comprehensive -WSS

comprehensive

author：comprehensive 2025-10-03 00:04:16 - browse：898

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： The Bio Revolution is changing business and society

entertainment

WSS

Should insurance cover cosmetic surgery?

Peter Hotez and the public health issue of online harassment

Protect nursing home residents from future pandemics

New research sheds light on how often breast cancer is overdiagnosed

After affirmative action ruling, medical educators look to 'holistic review'

J&J reports mixed data on next

knowledge

comprehensive

focus

Medicare proposal to cover medical devices draws a mixed reaction

Ozempic cut risk of death in diabetes patients with chronic kidney disease

23andMe had bad news about my health. I wish a person had delivered it

Bird flu makes raw milk dangerous to consume, mouse study finds

Medicare proposal to cover medical devices draws a mixed reaction

J&J reports mixed data on next

Affirmative action in medical school literally saved lives

How one medical school became remarkably diverse

Cancer drug shortages should be causing more outrage

Activists slam private health insurers over coverage restrictions

focus

Peter Hotez and the public health issue of online harassment

Hospitals need to get ahead of regulations on climate change

Congress: Prevent baby formula shortages by passing a new bill

Protect nursing home residents from future pandemics

BioMarin wins approval for gene therapy to treat hemophilia A

Stroke rates rising, especially in working

entertainment

focus

hotspot

knowledge